Navigation Links
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Date:3/11/2009

LOS ALTOS, Calif., March 11 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, today announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes (T2DM). INT131-007 is a 24 week, high dose active comparator (45mg Actos(R)) and placebo controlled study of INT131 at four doses in poorly controlled Type 2 diabetics.

"INT131-007 is an important study designed specifically to extend the encouraging findings from our Phase 2a study and demonstrate the unique properties of INT131, a potent insulin sensitizer, in patients with inadequately controlled type 2 diabetes mellitus (T2DM), said Alex DePaoli, M.D. InteKrin's Chief Medical Officer. "This Phase 2b study will provide critical efficacy, safety, and tolerability data to allow differentiation of INT131 from Actos(R) and inform dose selection for the Phase 3 program".

"InteKrin is very pleased to achieve this critical development milestone for INT131," remarked InteKrin's President and CEO, Denny Lanfear. "We anticipate having results from INT131-007 in the second half of this year concurrent with completion of all nonclinical and CMC efforts, enabling initiation of the INT131 Phase 3 program in 1H2010."

INT131 is a selective PPAR gamma modulator which has consistently demonstrated the separation of the powerful PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects. INT131 is well positioned to fulfill the unmet medical need for patients requiring safe treatment of insulin resistance, a key etiological feature in the onset and subsequent progression of T2DM, which remains inadequately addressed by current therapies.

About InteKrin (www.InteKrin.com):

InteKrin Therapeu
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... DIEGO , Feb. 9 ... developer and manufacturer of precision intravascular therapy guidance ... of coronary and peripheral vascular disease, announced today ... Catheter device line from Lumen Biomedical. Volcano became ... in May 2009 . This acquisition reinforces ...
(Date:2/9/2010)... Feb. 9 Glycemion Strategies, ... strategic initiatives for diabetic consumers and their professional ... Data Retrieval Program to benefit the 30,000 US ... diabetic clients they serve. ,, The ... is designed to provide real-time access to health ...
(Date:2/9/2010)... TechTeam Global, Inc ., (Nasdaq: ... technology outsourcing and business process outsourcing services, announced ... director of global life sciences services. Roumans will ... ongoing capability enhancement in support of TechTeam,s life ... of experience in the life sciences industry, most ...
Breaking Medicine Technology:Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 2Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 3Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 4Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 5Portrait Health(TM) Emergency Medical Data Retrieval Program-Glycemion Strategies Announces Free Membership for Diabetes Educators 2Portrait Health(TM) Emergency Medical Data Retrieval Program-Glycemion Strategies Announces Free Membership for Diabetes Educators 3TechTeam Global Appoints Life Sciences Services Director 2TechTeam Global Appoints Life Sciences Services Director 3Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 1Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 2Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 3Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 4Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 5Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 6Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 7Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 1Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 2Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 3Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 4Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 5Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 6FDA Approves Seasonal Flu Vaccine for 2009 2010 52150 1FDA Approves Seasonal Flu Vaccine for 2009 2010 52150 2FDA Approves Seasonal Flu Vaccine for 2009 2010 52150 3
(Date:2/9/2010)... the effect of vitamin D begins in the womb, ... Children born to mothers who drink lots of milk ... during pregnancy have a much lower risk of developing ... new study included 35,794 U.S. nurses whose mothers provided ... nurses were followed for 16 years, and 199 of ...
(Date:2/9/2010)... Feb. 9 The nation,s fourth ... (COPD), is now being measured by the Minnesota ... The program focuses on three major causes of ... triggered or made worse by environmental factors such ... asthma, heart attacks and COPD. ,, The ...
(Date:2/9/2010)... The following statement is ... M.D., President, American Medical Association: ,, (Logo: ... Medical Association is pleased to support First ... Let,s Move Campaign. As the nation,s largest ... address obesity and are committed to reenergizing ...
(Date:2/9/2010)... (Boston)- Researchers from Boston University,s Slone Epidemiology Center ... status and risk for type 2 diabetes in ... the online American Journal of Epidemiology , ... relationship between neighborhood socioeconomic status and incidence of ... cohort of African-American women. , Type 2 diabetes ...
(Date:2/9/2010)... Rhonda Roby , PhD, ... University of North Texas Center for Human Identification ... in recently identifying three murder victims of the Chilean ... The Chilean government contacted Roby in 2006 ... team of the victims, identification program for Patio 29. ...
Breaking Medicine News(10 mins):Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Neighborhood socioeconomic status and diabetes 2Health News:UNT Health Science Center's Roby Helps Identify Bodies of Chile's Patio 29 2Health News:UNT Health Science Center's Roby Helps Identify Bodies of Chile's Patio 29 3
... gene therapy, plastic surgeons have delivered cancer fighting proteins ... with a 79 percent reduction in tumor volume, according ... and Reconstructive Surgery, the official medical journal of the ... delivery technique, which has yet to be tested in ...
... May 8 Genomic Health,Inc. (Nasdaq: GHDX ) ... Chief Executive Officer, will present at the Bank of,America ... May 14,2008 at 3:20 p.m. Pacific Time., In ... will present at the 7th Annual JMP Securities Research ...
... researchers say , , THURSDAY, May 8 (HealthDay News) -- ... varies among patients, that growth tends to be faster ... may help in planning and evaluating screening programs, clinical ... Using a new mathematical model, the scientists were also ...
... Train-the-Trainer, summer program offers comprehensive interpreter ... ... Every day, language barriers,prevent professionals who work in healthcare ... In fact, the,guesswork associated with navigating around communication roadblocks often,becomes ...
... Colo., May 8 Regular daily activities can,expose us ... breathe as well as the,common body care and household ... each other when they,re combined in the body and,have ... illnesses,including cancer and internal organ damage, can result., ...
... CARLSBAD, Calif., May 8 Ortho Organizers, ... continuing education,programs, announces the release of their ... http://www.newscom.com/cgi-bin/prnh/20080508/LATH052 ), Ortho Organizers President ... fulfills a critical market demand with the ...
Other Medicine News:Health News:Skin flaps deliver cancer-fighting therapy, ASPS study reveals 2Health News:Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference 2Health News:Breast Cancer Tends to Grow Faster in Younger Women 2Health News:Culturesmart(TM) Breaks Language Barriers With Trained Medical Interpreters 2Health News:Culturesmart(TM) Breaks Language Barriers With Trained Medical Interpreters 3Health News:Natural Solutions May Issue Illustrates 'Cocktail Effect' of Everyday Toxins; Offers Tips to Reduce Toxic Load 2Health News:Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments 2
... MAGNETOM Trio with Tim™ (Total ... workflow, highest speed, and highest resolution ... up to 16, advanced applications can ... routine. MAGNETOM Trio with Tim is ...
... a set of features for handling business ... that allows staff to customize the system ... Medical Billing's electronic encounter forms, charges can ... care when used with Practice Partner Patient ...
... system is the Cambridge Heart ... (MTWA) testing platform which simplifies ... death risk stratification. This new ... it can be configured to ...
... For those who prefer the versatility that a ... consider the Volk g-2 trabeculum. It features the ... two opposing mirrors angled at 60 and 64 ... NF (no-flange/no-fluid) design. Volk recommends the "Flanged" model ...
Medicine Products: